Hostname: page-component-7bb8b95d7b-dtkg6 Total loading time: 0 Render date: 2024-09-13T19:48:25.479Z Has data issue: false hasContentIssue false
  • English
  • Français

Impact of Vancomycin Minimum Inhibitory Concentration on Mortality among Critically Ill Patients witn Methicillin-Resistant Staphylococcus aureus Bacteremia

Published online by Cambridge University Press:  02 January 2015

Christian J. Woods ,
Anindita Chowdhury ,
Vinay M. Patel  and
Andrew F. Shorr
Christian J. Woods
Affiliation:
Pulmonary and Critical Care Medicine Section, Washington Hospital Center, Washington, DC Georgetown University, Washington, DC
Anindita Chowdhury
Affiliation:
Pulmonary and Critical Care Medicine Section, Washington Hospital Center, Washington, DC
Vinay M. Patel
Affiliation:
Pulmonary and Critical Care Medicine Section, Washington Hospital Center, Washington, DC
Andrew F. Shorr*
Affiliation:
Pulmonary and Critical Care Medicine Section, Washington Hospital Center, Washington, DC
*
Pulmonary and Critical Care Medicine, Room 2A-69D, Washington Hospital Center, 110 Irving Street NW, Washington, DC 20010 (andrew.shorr@gmail.com)
Get access Rights & Permissions [Opens in a new window]

Abstract

We retrospectively evaluated 99 intensive care unit patients with methicillin-resistant Staphylococcus aureus bacteremia to determine whether having a vancomycin minimum inhibitory concentration (MIC) of 2 mg/L affected mortality. This MIC was found in 5.1% of patients and was associated with the probability of death (adjusted odds ratio, 13.9 [95% confidence interval, 1.1–171.2]) independent of other factors.

Type
Concise Communication
Information
Infection Control & Hospital Epidemiology , Volume 33 , Issue 12 , December 2012 , pp. 1246 - 1249
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2012

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Sakoulas, G, Moellering, RC JrIncreasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis 2008;46:S360–S367.10.1086/533592Google Scholar
2.Rybak, MJ, Leonard, SN, Rossi, KL, et al.Characterization of vancomycin-heteroresistant Staphylococcus aureus from the metropolitan area of Detroit, Michigan, over a 22-year period (1986 to 2007). J Clin Microbiol 2008;46:2950–2954.10.1128/JCM.00582-08Google Scholar
3.Lodise, TP, Graves, J, Evans, A, et al.Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother 2008;52:3315–3320.Google Scholar
4.Moise, PA, Sakoulas, G, Forrest, A, et al.Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 2007;51:2582–2586.10.1128/AAC.00939-06Google Scholar
5.Hawkins, C, Huang, J, Jin, N, et al.Persistent Staphylococcus aureus bacteremia: an analysis of risk factors and outcomes. Arch Intern Med 2007;167:1861–1867.10.1001/archinte.167.17.1861Google Scholar
6.Musta, AC, Riederer, K, Shemes, S, et al.Vancomycin MIC plus heteroresistance and outcome of methicillin-resistant Staphylococcus aureus bacteremia: trends over 11 years. J Clin Microbiol 2009;47:1640–1644.10.1128/JCM.02135-08Google Scholar
7.Price, J, Atkinson, S, Llewelyn, M, et al.Paradoxical relationship between the clinical outcome of Staphylococcus aureus bacteremia and the minimum inhibitory concentration of vancomycin. Clin Infect Dis 2009;48:997–998.10.1086/597359Google Scholar
8.Sader, HS, Fey, PD, Limaye, AP, et al.Evaluation of vancomycin and daptomycin potency trends (MIC creep) against methicillin-resistant Staphylococcus aureus isolates collected in nine U.S. medical centers from 2002 to 2006. Antimicrob Agents Chemother 2009;53:4127–4132.10.1128/AAC.00616-09Google Scholar
9.Soriano, A, Marco, F, Martinez, JA, et al.Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2008;46:193–200.10.1086/524667Google Scholar
10.van Hall, SJ, Lodise, TP, Paterson, DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis (in press).Google Scholar